Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
H.S. sophomore Avg
|
|
New words:
Aa, abundantly, accor, agonist, amortizable, amplification, argument, awaiting, Beta, bifurcation, blockade, Bond, CALGB, caption, carefully, Channel, chosen, commensurate, cooperative, CTEP, CuraScript, curve, dance, derecognition, diligent, disagree, divestiture, double, downstream, embedded, ErbB, escrow, farnasyl, finite, forfeiture, foundation, freestanding, gefitinib, Gemzar, GKA, hyperglycemia, iiib, imprisonment, inappropriate, Intraperiod, IRB, Iressa, Janumet, Janumettm, judgment, labor, malate, mammalian, momentum, motion, MTD, mTOR, multicenter, neural, notification, Notwithstanding, obsolescence, opposition, outlicense, outlicensed, outlicensing, overexpression, overfunded, PDGF, prudent, PTEN, rapamycin, rational, renegotiated, resizing, resubmitted, satisfaction, saxagliptin, securitized, simplified, Social, steady, sterile, streamline, streamlined, streamlining, strip, stroke, subunit, sunitib, synergistic, syringe, technique, Telcytatm, temporarily, tender, thirteen, thirty, TRIBUTE, true, unclear, underfunded, unexchanged, unresectable, vandetanib, Vectibix, Vectibixtm, weighing, willfully, Xyotaxtm, Zactima, Zactimatm
Removed:
abroad, absence, acceleration, accrual, achieving, add, AICPA, assist, assuming, automated, awarded, belief, billion, Birmingham, Butler, California, Celgene, center, chemistry, collateral, committing, complement, considerable, created, customer, debilitating, description, dilute, discovering, diversified, emerge, enhancement, error, establishment, exchanged, execution, exisulind, experiencing, explore, exportation, exported, extended, facing, fact, fast, forfeited, forgiven, franchise, GlaxoSmithKline, grow, growing, guiding, improved, infrastructure, infusion, integrity, intravenously, investing, irrevocable, john, liposomal, membership, merged, Mexico, mitigate, moderate, move, mutual, newly, noted, occurring, oxaliplatin, percent, pharmacology, pigmentation, pilot, plc, pledged, positioned, prime, priority, profiling, prominent, proportionate, proportionately, prove, provisional, published, quotation, rare, recording, renewed, reorder, restructuring, retail, retainer, revision, safer, satisfactory, Seiyaku, shift, shorter, Sinclair, subcontracting, subset, superior, synthase, Tanabe, Tarrytown, throughput, thymidylate, toxicological, track, transfer, transferring, transitional, treating, unapproved, vi, virtue
Filing tables
Filing exhibits
Related press release
OSIP similar filings
Filing view
External links
EXHIBIT 32.2
OSI PHARMACEUTICALS, INC.
CERTIFICATION PURSUANT TO
18 U.S.C. § 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of OSI Pharmaceuticals, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2006 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Michael G. Atieh, Executive Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
| (1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and | |
| (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. |
| /s/ MICHAEL G. ATIEH | |
| Michael G. Atieh | |
| Executive Vice President and Chief | |
| Financial Officer |
Date: February 28, 2007
129